Profusa (PFSA) Total Non-Current Liabilities (2021 - 2026)
Profusa's (PFSA) quarterly Total Non-Current Liabilities came in at $17.6 million in Q1 2026, up 23.67% year-on-year from $14.3 million in Q1 2025, and down 2.53% quarter-over-quarter from $18.1 million in Q4 2025.
Profusa (PFSA) Total Non-Current Liabilities (2021 - 2026) Analysis & Trends
Profusa's Total Non-Current Liabilities history runs 6 years deep, the most recent figure standing at $17.6 million for Q1 2026.
- On a quarterly basis, Total Non-Current Liabilities rose 23.67% year-over-year to $17.6 million in Q1 2026; TTM through Mar 2026 was $17.6 million, a 23.67% increase from a year earlier, with the FY2025 full-year figure at $18.1 million, down 67.03% from the prior year.
- Total Non-Current Liabilities retreated to $17.6 million in Q1 2026 per PFSA's latest filing, from $18.1 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $54.9 million in Q4 2024 and bottomed at $85588.0 in Q1 2022.
- The 5-year median for Total Non-Current Liabilities is $5.0 million (2023), against an average of $9.5 million.
- Across the five-year window, Total Non-Current Liabilities plunged 79.91% in 2022 and jumped 4619.15% in 2023, its largest moves.
- Year by year, Total Non-Current Liabilities stood at $1.4 million in 2022, then jumped by 253.09% to $5.0 million in 2023, then soared by 992.3% to $54.9 million in 2024, then plunged by 67.03% to $18.1 million in 2025, then declined by 2.53% to $17.6 million in 2026.
- Per Business Quant, the three latest PFSA Total Non-Current Liabilities figures stand at $17.6 million (Q1 2026), $18.1 million (Q4 2025), and $19.4 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | - |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 20.94 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 41.44 Bn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 41.88 Bn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 2.64 Bn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 3.53 Bn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 9.85 Bn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 24.21 Bn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | 3.57 Bn |
| 10 | Profusa | 23,566.40 | -351,433.60 | - | 17.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 17.64 Mn |
| Dec 31, 2025 | 18.10 Mn |
| Sep 30, 2025 | 19.36 Mn |
| Jun 30, 2025 | 5.70 Mn |
| Mar 31, 2025 | 14.26 Mn |
| Dec 31, 2024 | 54.90 Mn |
| Sep 30, 2024 | 5.17 Mn |
| Jun 30, 2024 | 5.08 Mn |
| Mar 31, 2024 | 4.33 Mn |
| Dec 31, 2023 | 5.03 Mn |
| Sep 30, 2023 | 3.37 Mn |
| Jun 30, 2023 | 3.19 Mn |
| Mar 31, 2023 | 4.04 Mn |
| Dec 31, 2022 | 1.42 Mn |
| Sep 30, 2022 | 400,282.00 |
| Jun 30, 2022 | 160,243.00 |
| Mar 31, 2022 | 85,588.00 |
| Dec 31, 2021 | 7.08 Mn |